← Back to Search

Glutamate Receptor Antagonist

Dipraglurant for Parkinson's Disease

Phase 2 & 3

Waitlist Available

Research Sponsored by Addex Pharma S.A.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline (day 1) to week 52

Awards & highlights

Study Summary

This trial will study the long-term effects of a drug called dipraglurant on patients with Parkinson's disease.

Eligible Conditions

Parkinson's Disease
Dyskinesia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline (day 1) to week 52

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline (day 1) to week 52

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) to week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Long-term safety and tolerability of dipraglurant as measured by incidence of adverse events

Secondary outcome measures

Evaluate the continued utility of dipraglurant on dyskinesia as assessed by a change-from-baseline score on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dipraglurant TIDExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Addex Pharma S.A.Lead Sponsor

7 Previous Clinical Trials

1,018 Total Patients Enrolled

Media Library

Dipraglurant (Glutamate Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05116813 — Phase 2 & 3

Parkinson's Disease Research Study Groups: Dipraglurant TID

Parkinson's Disease Clinical Trial 2023: Dipraglurant Highlights & Side Effects. Trial Name: NCT05116813 — Phase 2 & 3

Dipraglurant (Glutamate Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05116813 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other examples of Dipraglurant being used in a clinical setting?

"Dipraglurant was first studied in 2021 by University of Pennsylvania. Since then, there have been 2 completed trials and 2 ongoing trials. Many of the ongoing studies are based in Kansas City, Kansas."

Answered by AI

Are people with the target condition able to participate in the research at this time?

"From what is published on clinicaltrials.gov, it appears that this research study is still recruiting patients. The trial was first advertised on October 25th, 2021 and was most recently updated on April 18th, 2022. The aim is to have 140 participants enrolled from 7 different locations."

Answered by AI

Who does this trial hope to enroll as participants?

"Researchers conducting this clinical trial are looking for 140 individuals that have been diagnosed with parkinson disease. These patients must be between 30 and 85 years old and willing to maintain a stable regimen of antiparkinson's medications for the first month of the study. Additionally, participants must be able to take the study drug 3 times daily with at least 3 hours in between each dose."

Answered by AI

Does this research project restrict participation to adults under 30 years old?

"According to the eligibility requirements listed, the age range for potential participants in this trial are those between 30-85 years old. There are currently 39 clinical trials underway for patients under 18 and 531 for senior citizens."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

2021. "Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05116813.